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Abstract
Introduction
Immunosuppressive agents (ISA) have been used in multiple sclerosis (MS) for decades,
frequently as off label licensed therapies. Given the new MS treatment landscape, what
place do ISA have in combating MS?
Methods
We conducted a retrospective multicentre study to investigate the frequency of ISA pre-
scription in 17 Italian MS centres, and to describe the clinical factors related to ISA use.
Results
Out of 6,447 MS patients, 2,034 (31.6%) were treated with ISA, with Azathioprine being the
most frequently used ISA overall. MS patients treated with ISA alone were more frequently
affected by the progressive course (both primary and secondary) of the disease (RRR 5.82,
95% CI 4.14–8.16, p<0.0001), had higher EDSS (RRR 3.69, 95% CI 2.61–5.21, p<0.0001),
higher assignment age (RRR 1.04, 95% CI 1.03–1.06, p<0.0001) than patients treated with
only disease modifying drugs (DMDs).
Conclusions
Progressive course, higher EDSS, higher assignment age were the strongest predictors of
ISA prescription and use in our population.
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Introduction
The proper choice of a treatment represents a major challenge in the management of the
patients with MS [1].
From the beginning of its description, MS pathogenesis has been ascribed to a deviation of the
immune system [2]. Immunosuppressive agents (ISA) are inhibitors of crucial components of the
immune system and they were used early in MS treatment; but their use was frequently off-label
[3]. Two classes of immunomodulatory agents (DMDs) have been approved for the treatment of
relapsing–remitting MS (RR-MS), that is interferon-β (INFs), and glatiramer acetate (GA) [4].
DMDs are able to shift immune responses from a pro-inflammatory toward an anti-inflamma-
tory status; thus they were considered first-line options inMSmanagement to modify the disease
course inMS [4]. Later, mitoxantrone (an ISA), has been approved for treatment of active forms
of RRMS and secondary progressive MS (SPMS) [5]. Furthermore, in the last years a number of
oral ISA became, or are going to be, available in the MS management as first-line option [6].
The treatment landscape of MS is dramatically changing and the role of ISA in MS therapy
scenario need to be deeply reconsidered and rewritten. Data about the frequency of their use
were collected in the past, involving different countries worldwide; and the frequency of ISA
prescription was found to be around 10% [7–8]. There were strong differences in frequency of
ISA treatments per country [7–8]. To date we were unable to identify any large-scale clinical
trials that characterize ISA prescription use in MS patients. Nonetheless, ISA continue to be
used in MS patients, given that some patients are refractory to more conventional therapies or
experienced contraindications to the use of more modern MS treatments such as with fingoli-
mod or natalizumab. We designed and performed this study in Italy (involving the two princi-
pal regional areas) looking first at the frequency of ISA use. Moreover, we described the clinical
features of MS patients who were ISA exposed to start questioning how and when it is possible
thinking about ISA use in the clinical practice.
Our work could help the clinical neurologists to gain more insight in ISA prescription and
use in MS therapy scenario and to consider how the use of ISA must be critically re-evaluated
in the light of the recent changes in MS treatment landscape.
Methods
A retrospective analysis of prospectively collected data was performed. The settings were refer-
ral subspecialty MS clinics in Italy. Twenty-five Italian MS centres (members of Italian iMED-
Web registry) were asked to participate in survey. Seventeen MS centres in the two different
Italy’s regional area (eight in the North-Centre area, eight in the South-Sicily Island area) con-
firmed the participation in the study.
Clinical and demographical data of MS patients were recorded at each of the collaborating
centers using the offline medical record iMED (Serono International SA, Geneva, Switzerland)
and then uploaded to the Italian iMedWeb registry. The use of iMED as a research platform
was approved by the local human research ethics committee at all participating centers. Quality
assurance of clinical data was maintained by inbuilt data quality checking in the iMED local
record system. To ensure consistency of Expanded Disability Status Score (EDSS) evaluations
all neurologists completed the Neurostatus certification (http://www.neurostatus.net) or pro-
vided evidence of prior completion of this certification.
We searched through iMED software querying ISA and DMDs prescription. We identified
two main groups of treated patients with MS: a group treated with ISA and a group treated
with DMDs. The inclusion criteria were: i) diagnosis of MS according to Poser or McDonald
criteria [9–10]; ii) disease duration of at least three years (evaluated as difference in time: last
visit-onset disease); iii) at least three neurological evaluations performed by senior, trained
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neurologists in the MS diagnosis and management. We did not take in account patients being
enrolled in experimental phase III studies. To avoid clinical misclassification we merged the
secondary progressive and primary progressive patients below the umbrella definition of pro-
gressive forms, independently on their “activity status” [11]. ISA group included the patients
treated at least one time with one or more of four drugs: azathioprine (AZA), cyclophospha-
mide (Cyc), methotrexate (MT) and mitoxantrone (MTX).
We divided the ISA group in three different subgroups: patients treated with ISA alone
(arbitrarily defined as “pure ISA” therapy regimen), patients treated with ISA as first-therapy
and then with DMDs (defined as “induction” therapy regimen) and patients treated with
DMDs as first-therapy and then ISA (defined as “escalation” therapy regimen).
The fourth subgroup included DMDs patients, that is all MS patients treated with one or more
of the different INFs formulations [Avonex1 (Interferon beta-1a intramuscular once a week; Beta-
feron1 (interferon beta-1b subcutaneous every second day); Extavia1 (Interferon beta-1b subcu-
taneous every second day) Rebif1 (Interferon beta-1a, at dosage of 22 or 44 micrograms
subcutaneous three times per week and Copaxone1 (Glatiramer Acetate subcutaneous every day)].
AZA was prescribed at variable doses ranging from 50 to 200 mg daily orally administered.
Cyc was prescribed intravenously every month, 750–2000 mg per month with a cumulative
dose of 4.800–30.000 mg per patient. MT was prescribed at doses of 7.5–15 mg weekly in 1–2
different oral administrations. MTX was prescribed intravenously at doses of 10–20 mg
monthly for a cumulative dose of 60–200 mg.
The date of the enrollment visit was the date of the first therapy prescription and adminis-
tration (ISA or DMDs). The EDSS [12] was recorded at baseline and at least every 3 months
subsequently to determine the disability’s accrual.
Ethics: the study received the approval of the coordinating centre Ethical Committee (at
Catania University). The participating centres informed their ethical committee, before making
available informatics records of their patients at each centre. All of the recruited patients had
signed an informed consent.
Statistical analysis
Baseline characteristics of whole population were reported as frequencies and percentages for
categorical variables and mean ± standard deviation (sd) for continuous variables. Disease
duration was also reported as categorical variables. In particular, it was dichotomized according
to clinical relevant cut off [13–15].
Patients were divided into four groups based on assigned therapy as previously indicated.
Comparisons among multiple groups and associations with clinical parameters were per-
formed with univariate multinomial logistic regression models. Multivariable analyses, with
stepwise selection, were also conducted to investigate the effect of some confounding factors on
the outcome of interest. Evaluated variables were those resulting significant at univariate analy-
ses. The results were presented as relative risk ratios (RRR) with corresponding 95% confidence
intervals and p-values. In a second step, the attention was focused on two main subgroups (all
ISA vs DMDs). In this case simple and multiple logistic models were considered. Cochran-
Armitage test was used to test for trend among proportions. The statistical significance was
achieved at a p-value<0.05. All the analyses were performed using the Statistical Analysis Sys-
tem (SAS) Package, Release 9.2 (SAS Institute, Cary, NC, USA).
Results
From a total sample of 11,335 MS patients, 6,447 (83%) patients were considered eligible for
frequency analyses [S1 Table]. A number of 4,413 (68.4%) were treated with DMDs (INFs or
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GA) and 2,034 (31.6%) with ISA. Out of 2,034, 580 were classified as pure ISA, 501 were in
induction scheme and 953 were in escalation scheme (Fig 1). Out of 2,034 ISA treated patients,
AZA was the most frequently used in monotherapy (41.4%), followed by MTX (24,4%), then
Cyc (7.9%) and MT (4.4%). The 21.9% of the whole group assigned to ISA treatment had used
more than one single ISA drug.
A total of 4,624 patients were affected by RRMS and 1,006 suffered from progressive forms
of MS (PFMS). The remaining 817 patients with MS were not yet clinical classified, because
they had no the international used criteria [11–16] to be assigned to one of the two MS groups.
EDSS evaluations were disposable in 4,202 patients and about 78% of patients had and EDSS
value lower than 4.0. See Table 1.
Table 2 shows the results of univariate multinomial logistic regression analyses. Regarding
the age at MS onset, pure ISA subgroup had an older age, than DMDs and ISA subgroup
(p<0.0001). Moreover, pure ISA group had significant higher assignment age than DMDs
(p<0.0001). Regarding clinical characteristics, we found that pure ISA subgroup had longer
disease duration (that is equal/more than five years) than DMDs. All ISA subgroups (pure,
induction, escalation) experienced more frequently progressive course of the disease than
DMDs (p<0.0001 for all). All ISA subgroups showed higher level of disability (EDSS value
equal or higher of 4.0) (p<0.0001 for all) than DMDs group.
Fig 1. Shows the distribution of ISA subgroups in our cohort.
doi:10.1371/journal.pone.0157721.g001
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The multivariable multinomial logistic analyses confirmed the univariate results (Table 3).
Pure ISA subgroup had an older assignment age, more frequently PFMS and higher EDSS
value than DMDs. Also induction and escalation ISA subgroups showed more frequently
Table 1. Patients’ characteristics at baseline.
Variable Number (%) or mean±sd
Number 6,447
Age at onset 28.51±9.34
Assignment age 36±10.44
Disease duration
<5 3,328 (82.13)
5 3,119 (48.38)
Disease course
RR 4,624 (82.13)
PP 1,006 (17.87)
EDSS
<4 3,291(78.32)
4 911(21.68)
SEX
M 2,097 (32.53)
F 4,350 (67.47)
Geographical areas
Centre-North 2,670 (41.41)
South-Island 3,777(58.59)
doi:10.1371/journal.pone.0157721.t001
Table 2. Univariate multinomial logistic regression analyses.
Effect n Therapy (ref = DMDs) RRR(95% CI) p-value
Age at onset 580 Pure ISA 1.05(1.04–1.06) <0.0001
501 Induction 1.00(0.99–1.01) 0,339
953 Escalation 0.99(0.99–1.01) 0,87
Assignment age 580 Pure ISA 1.08(1.07–1.09) <0.0001
501 Induction 1.01(0.99–1.02) 0,108
953 Escalation 1(0.99–1.01 0,972
Disease duration 580 Pure ISA 2.59(2.15–3.12) <0.0001
(= >5 vs <5) 501 Induction 1.05(0.87–1.26) 0,638
953 Escalation 1.07(0.93–1.23) 0,358
Disease course 518 Pure ISA 15.87(12.89–19.54) <0.0001
(PP vs RR) 435 Induction 5.22(4.16–6.55) <0.0001
759 Escalation 3.54(2.91–4.30) <0.0001
EDSS 336 Pure ISA 14.28(11.07–18.43) <0.0001
(= >4 vs <4) 195 Induction 4.81(3.56–6.48) <0.0001
515 Escalation 2.10(1.68–2.62) <0.0001
SEX 580 Pure ISA 1.37(1.15–1.64) 0,0006
(M vs F) 501 Induction 1.29(1.06–1.56) 0,009
953 Escalation 1.27(1.09–1.47) 0,002
Geographical areas 580 Pure ISA 1.68(1.39–2.02) <0.0001
(South-Islands vs Centre-North) 501 Induction 1.05(0.87–1.26) 0,643
953 Escalation 1.33(1.15–1.54) 0,0001
doi:10.1371/journal.pone.0157721.t002
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PFMS and higher EDSS value than DMDs. The findings were all statistically significant. We
also found that in South-Island area there was higher frequency of pure and escalation ISA
than DMDs compared with the Centre-North area (p<0.05 and<0.01, respectively).
Paying attention to the relation between the assigned therapy and the disease course it could
be noticed that there was a decreasing percentage of progressive forms from pure ISA subgroup
(the highest) to DMDs group (the lowest) (Fig 2). The trend showed in Fig 2 was confirmed by
the Cochran-Armitage test (p<0.0001).
At the univariate logistic regression analyses (Table 4) all patients treated with ISA (pure,
induction, escalation subgroups) were older at onset and at therapy assignment than DMDs
group (p<0.0001). They also experienced longer disease duration (p<0.0001), PFMS (p<0.0001)
and higher EDSS (p<0.0001). Furthermore these patients were more frequently men (p<0.0001)
and settled in the South-Island area (p<0.0001). The multiple logistic regression confirmed only
disease course, EDSS and geographical areas as independent predictors of ISA therapy (Table 5).
Discussion
About 30% of our MS patients had received at least one ISA prescription. MS patients who
were older at age of therapy assignment and with higher disability (in terms of EDSS and
PFMS course), have more frequently used ISA as pure ISA regimen. Moreover, pure ISA were
more frequently prescribed in the South-Island area of our country, Italy. Previously, a world-
wide survey about ISA prescription (including AZA, Cyc, MT, MTX) in 191 MS centres
showed a mean percentage of ISA use about 10% [7]. Regarding Europe, France had the highest
percentage (32.5%), and Italy had 12.7% of ISA use [7].
This study has potential limits, the first one is the retrospective design, although data were
prospectively collected in each centre on patients who were regularly followed up. It also has
the limit to miss data regarding patients without inclusion criteria (almost 3 years disease dura-
tion), or patients lost at follow-up (mainly because of moving to other centres). Moreover, the
missing data in EDSS field, which did not invalidate the results.
In the last years, MS therapeutic armamentarium has dramatically grown up [17]. The
introduction of new drugs with immunosuppressant profile has led the MS clinician to take in
account an earlier and more aggressive approach in the MS treatment [17]. Nevertheless, the
paucity of long term safety data, may have limited their use in the clinical practice. So, ISA may
represent a useful therapeutic option to satisfy a new therapeutic approach aimed at a more
aggressive and even earlier treatment with a well-known profile of toxicity.
Table 3. Multivariable multinomial logistic regression analyses.
Effect Mean± SD or n (%) Therapy (ref = DMDs) RRR(95% CI) p-value
Assignment age 44.14±12.02 Pure ISA 1.04(1.03–1.06) <0.0001
35.9±10.7 Induction 0.98(0.96–0.99) 0,006
35.12±9.48 Escalation 0.99(0.98–1.00) 0,057
Disease course 315(60.81) Pure ISA 5.82(4.14–8.16) <0.0001
(PP vs RR) 147(33.79) Induction 3.24(2.07–5.06) <0.0001
195(25.69) Escalation 2.91(2.09–4.05) <0.0001
EDSS 237(70.54) Pure ISA 3.69(2.61–5.21) <0.0001
(= >4 vs <4) 87(44.62) Induction 3.33(2.21–5.02) <0.0001
134(26.02) Escalation 1.57(1.16–2.12) 0,003
Geographical areas 397(68.45) Pure ISA 1.45(1.06–1.97) 0,018
(South-Islands vs Centre-North) 288(57.49) Induction 1.29(0.90–1.84) 0,168
603(63.27) Escalation 1.36(1.08–1.72) 0,009
doi:10.1371/journal.pone.0157721.t003
ISA Use in Italy: A Multicenter Survey
PLOS ONE | DOI:10.1371/journal.pone.0157721 June 27, 2016 6 / 11
Table 4. Univariate logistic regression analyses performed on all ISA patients vs others.
Effect mean±sd or n (%) OR (95% CI) p-value
Age at onset 29.46±10 1.016(1.010–1.022) <0.0001
Assignment age 37.88±9.92 1.025(1.02–1.03) <0.0001
Disease duration 1089(53.54) 1.35(1.22–1.50) <0.0001
(= >5 vs <5)
Disease course 657(38.38) 6.37(5.50–7.38) <0.0001
(PP vs RR)
EDSS 458(43.79) 4.65(3.97–5.44) <0.0001
(= >4 vs <4)
SEX 743(36.53) 1.30(1.16–1.45) <0.0001
(M vs F)
Geographical areas 1288(63.32) 1.34(1.20–1.49) <0.0001
(South-Islands vs Centre-North)
doi:10.1371/journal.pone.0157721.t004
Fig 2. Shows the relation between the assigned therapy and the disease course in alla ISA subgroups and DMDs group.
doi:10.1371/journal.pone.0157721.g002
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In a recent non-inferiority trial 150 patients with RRMS were randomized to receive AZA 3
mg/kg daily (n = 77) or INF beta-1a 22 or 44 μg (n = 69) or INF beta-1b (n = 4) for two years.
The intent-to-treat analysis was done on 68 and 63 patients, respectively. Annualized relapse
rates were not significantly different between the AZA and INF-beta groups in the first (0.37 vs
0.47; p<0.05 and second (0.18 vs 0.29; p<0.05) years and, when combined for the two years,
the annualized relapse rate was lower in the AZA group (0.26 vs 0.39; p<0.05 p = 0.07) [18]. In
the AZA group there were more treatment discontinuations than in the INFs group because of
adverse events [18]. These interesting data showed that AZA may be as effective as INFβ in
RRMS as first-line therapy and shed new light on the possibility that MS physicians might use
ISA as a suitable first line-drug to be prescribed. Obviously, such a strategy requires closer clini-
cal monitoring during the first years, in particular to titrate the dose according to the lympho-
cyte count, and in general to manage all alerts reflecting a possible individual susceptibility. On
the other hand, for some patients, ISA could provide a higher quality of life without the flu-like
symptoms of INF or because of a less invasive route of administration, and with a known side
effect profile, which could be easily monitored.
Progressive course of MS (both primary and secondary) and higher level of disability were
correlated to overall ISA prescription in our study. These data are in line with previous reports
about a higher ISA use in PFMS, that is in more impaired patients, and moreover, a preferred
use as second-line therapy [8]. However, in our sample, the 39.2% of patients who had used
ISA alone (pure ISA subgroup) did not have PFMS; and the percentage of patients with RRMS
who had used ISA in escalation or induction was around 70%.
Two different therapeutic approaches are actually used in MS: escalation and induction
therapy. Escalation therapy consists of starting, in the early phases of the disease, with first line
DMDs (INFs, GA, teriflunomide, dimethyl fumarate) and if DMDs are ineffective or partially
effective, a switch to second line drugs (MTX, natalizumab, fingolimod and other off-label
used ISA as AZA, Cyc, MTX) and, in case of more failures, a third line options, such as alemtu-
zumab or autologous hematopoietic transplant could be considered[17]. Induction therapy
consists of the early use of more aggressive therapy (such as ISA) followed by long-term main-
tenance treatment, generally with DMDs [19]. The use of natalizumab and fingolimod as first
line drugs is indicated for aggressive forms of RRMS [17]. Both escalating and induction strate-
gies can be successfully applied on the basis of clinical and radiological data; apart from clini-
cally aggressive RRMS, for which induction treatment could be regarded as the first line of
treatment. The use of more aggressive drugs in MS will make it particularly important to have
long term safety data.
Both MTX and Cyc have the limit of cumulative doses [20–23]. Fewer concerns are raised
by AZA; it was reported that long periods of treatment with this drug could expose patients to
the risk of malignancies [24].
In the last decades, the economic burden of the disease has also received increasing atten-
tion, especially when considering efforts aimed to control public expense along with the decline
Table 5. Multivariable logistic regression analyses performed on all ISA patients vs others.
Effect mean±sd or n (%) OR(95% CI) p-value
Disease course 657 (38.38) 4.03(3.19–5.09) <0.0001
(PP vs RR)
EDSS 458 (43.79) 2.44(1.97–3.01) <0.0001
(= >4 vs <4)
Geographical areas 1288(63.32) 1.37(1.14–1.64) 0,0007
(South-Islands vs Centre-North)
doi:10.1371/journal.pone.0157721.t005
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of available resources for the healthcare services in Western countries [23]. Costs of MS are
highly due to the chronic nature of the disease, the need for hospitalization during phases of
severe relapses and to the gradual increase in disability, which may necessitate assistance with
daily life activities.
In Italy, MS is the second CNS disorder for cost per patient, with an estimated cost of
around €25,000 per MS patient/year; the costs of DMDs were significantly lower for patients
with EDSS scores higher than 4.0 [25]. All of these reasons underline as the therapeutic deci-
sions of the MS physician have to take into account the related economic weight. Probably,
among the reasons of the prominent use of ISA in South-Island area of Italy, there was a differ-
ent economic organization of the local healthcare system [25].
Several new drugs have recently demonstrated their efficacy in RRMS in randomized con-
trolled phase III trials, and have been recently approved in some countries or their approval
can be expected in the near future [26]. The future challenge will be to choose the most effica-
cious and safe drug for the individual patient. Biomarkers that help to predict these issues in
the individual are mandatory [27]. The course of MS varies between individuals and intra-indi-
vidual during the course of the disease: some patients accumulate minimal disability over their
lives, whereas others experience a rapidly disabling disease course. This latter subset of patients
show a rampant progression of disability over a short time period, and they are referred to
have an 'aggressive' MS. Treatment of patients with aggressive MS is challenging, and optimal
strategies have yet to be defined.
Given potentially severe side-effects of newer agents for the treatment of patients with MS,
including monoclonal antibodies that possess immunosuppressive properties, it is likely that
the established immunosuppressant approach will not be replaced in the therapy of MS in the
near future. A selected group of highly active MS patients may benefit from a “hit hard and
“early” approach, driven by the essential aim to suppress the inflammatory cascade which
plays a crucial role in the early stage of the disease. It is clear that more investigations are
needed to clarify the optional therapeutic strategies for MS treatment.
Names of drugs:Avonex1 (Interferon beta-1a intramuscular once a week); Betaferon1
(Interferon beta-1b subcutaneous every second day); Extavia1 (Interferon beta-1b subcutane-
ous every second day); Rebif1 (Interferon beta-1a, at dosage of 22 or 44 micrograms subcuta-
neous three times per week, Copaxone1 (Glatiramer Acetate subcutaneous every day);
Azathioprine; Metotrexate;Mitoxantrone; Cyclophosfamide; Tysabri1 (natalizumab); Gyle-
nia1(Fingolimod).
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